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Background	 Visual	 analogue	 scales	 (VAS)	 are	 simple	 symptom	assessment	 tools	which	have	not	
been	validated	in	interstitial	 lung	disease	(ILD).	Simple	measures	of	ILD	disease	burden	would	be	
valuable	 for	 non-specialist	 clinicians	 monitoring	 disease	 away	 from	 ILD	 specialist	 centres.	 This	
study	aimed	to	validate	VAS	to	assess	change	in	dyspnoea,	cough	and	fatigue	in	ILD,	and	to	define	
the	minimal	clinically	important	difference	(MCID)	for	change	in	these.	
Methods	 64	 patients	with	 ILD	 completed	 VAS	 for	 dyspnoea,	 cough	 and	 fatigue.	 Baseline	 King’s	
Brief	 ILD	 questionnaire	 (K-BILD)	 scores,	 lung	 function	 and	 6-minute	 walk	 test	 results	 were	
collected.	Tests	were	 repeated	3-6	months	 later,	 in	addition	 to	a	7-point	 Likert	 scale.	The	MCID	
was	estimated	using	median	change	 in	VAS	 in	patients	who	reported	“small	but	 just	worthwhile	
change”	 in	 symptoms	 at	 follow-up.	 Methods	 were	 repeated	 in	 a	 validation	 cohort	 of	 31	 ILD	
patients	to	confirm	findings.	
Results	 VAS	 scores	 were	 significantly	 higher	 for	 patients	 who	 reported	 a	 “small	 but	 just	
worthwhile	change”	 in	symptoms	versus	“no	change”	or	“not	worthwhile	change”	 (p<0.01).	The	
MCID	 for	 VAS	Dyspnoea	was	 estimated	 as	 22.0mm	and	 14.5mm	 for	 VAS	 Fatigue.	 These	 results	
were	reproducible	in	the	validation	cohort.	Results	were	not	significant	for	VAS	Cough.	Change	in	
VAS	Dyspnoea	 correlated	with	 change	 in	K-BILD	 (r=-0.51,	 p<0.01),	 forced	 vital	 capacity	 (r=-0.32,	
p=0.01)	and	6-minute	walking	distance	(r=-0.37,	p=0.01).	










Interstitial	 lung	 diseases	 (ILDs)	 are	 chronic,	 progressive	 disorders	 of	 the	 lung	 parenchyma	3	
associated	with	significant	morbidity	and	mortality1.	Despite	recent	advances	in	ILD	therapies3,	the	4	
care	 of	 a	 large	proportion	of	 ILD	patients	 focuses	 on	 the	management	 of	 dyspnoea,	 cough	 and	5	




Increasingly,	 the	model	of	care	 for	patients	with	 ILD	 is	of	shared	care	between	a	 local,	 referring	10	
centre	 and	 a	 specialist	 ILD	 centre.	 	 This	 care	may	 incorporate	 community	 nurses,	 non-specialist	11	
physicians	 and	 other	 allied	 health	 professionals.	 	 Simple,	 quickly	 completed	 tools	 to	 assess	12	








The	 aim	 of	 this	 study	 was	 to	 investigate	 whether	 VAS	 are	 valid	 tools	 for	 assessing	 change	 in	21	






This	 was	 a	 prospective	 observational	 study.	 Ethical	 approval	 was	 granted	 by	 East	 of	 Scotland	28	
Research	Ethics	Service	and	all	participants	provided	written	consent.	Patients	with	a	range	of	ILDs	29	
were	recruited	consecutively	from	the	Bristol	ILD	service	at	North	Bristol	NHS	Trust	from	January-30	









respiratory	 disease	 (Figure	 1)12.	 	 	 These	 assessments	 were	 completed	 with	 the	 assistance	 of	37	
respiratory	 physiologists	 supervising	 their	 lung	 function	 testing.	 	 At	 follow-up	 after	 3-6	months,	38	
patients	completed	a	second	VAS,	a	7-point	Likert	scale,	lung	function	tests,	6MWT	and	repeated	39	




the	 centre	 of	 the	 point	 recorded	 by	 the	 patient12.	 Change	 in	 VAS	 was	 calculated	 from	 the	44	
difference	 between	 VAS	 score	 at	 initial	 and	 follow-up	 visits.	 In	 analysing	 results,	 the	 relative	45	







are	 validated	 measures	 with	 described	 MCID,	 used	 in	 prognostication	 and	 monitoring	 for	53	
ILD15,18,19.	Patient-based	anchors	were	the	7-point	Likert	scale14,20	and	the	K-BILD	tool17.	54	
	55	
Estimates	 of	 MCID	 were	 compared	 to	 distributional	 methods	 including	 effect	 size	 (ES)	 and	56	




score	 (in	 this	 case	 100mm),	 and	 the	 range	 of	 the	 outcome	measure	 is	 6	 standard	 deviations21.	61	
Therefore	the	ERES	MCID	was	calculated	by	dividing	100	by	6.		Additionally,	patients	estimated	the	62	




Statistical	 analyses	 were	 performed	 using	 MiniTab17	 Statistical	 software23.	 	 All	 patients	 who	67	









Correlations	between	change	 in	VAS	and	change	 in	forced	vital	capacity	 (FVC),	diffusing	capacity	74	
for	 carbon	 monoxide	 (DLCO),	 6MWT	 and	 K-BILD	 scores	 were	 assessed	 using	 Spearman’s	 Rank	75	
correlation	coefficient.	The	strength	of	correlations	were	determined	according	to	absolute	values	76	
of	 the	 coefficient;	 large	 (r>0.5),	 moderate	 (r=0.5-0.3)	 and	 small	 (r=0.1-0.3)24.	 	 Any	 influence	 of	77	













The	primary	outcome	of	 the	study	was	 the	MCID	estimated	 from	the	median	change	 in	VAS	 for	91	
patients	reporting	a	“small	but	 just	worthwhile	change”	on	the	7-point	Likert	scale	at	 follow-up.	92	
Other	 pre-specified	 secondary	 outcomes	 included	 correlation	 of	 change	 in	 VAS	 with	 change	 in	93	






























in	 VAS	 increased	 as	 Likert	 response	 increased	 for	 all	 symptoms.	 The	 MCID	 for	 change	 in	 VAS	121	
Dyspnoea	 (VASD)	was	 22.0mm,	 equating	 to	 a	 “small	 but	 just	worthwhile	 change”	 on	 the	 Likert	122	
scale.	Moods	median	 showed	 statistically	 significant	 differences	 in	 change	 in	 VASD	 between	 all	123	
Likert	groups	(p<0.001,	95%	CI,	12-35mm)	(Table	2,	Figure	3A).	124	
	125	
The	 MCID	 for	 change	 in	 VAS	 Fatigue	 (VASF)	 was	 14.5mm.	 There	 were	 statistically	 significant	126	






respectively)	 (Table	 3).	 Patient-opinion	 and	 anchor-based	 estimates	 of	 VASD	MCID	were	 similar	133	















































The	 selection	 of	 clinical	 parameters	 to	 which	 to	 compare	 the	 VAS	 was	 based	 on	 those	 used	175	
routinely	 in	 this	 ILD	centre.	 	As	such,	we	did	not	compare	VASC	and	VASF	to	specific	cough	and	176	
fatigue	questionnaires.		This	may	limit	the	interpretation	of	our	results,	however	the	VASC	did	not	177	
reveal	significant	changes	over	time.		The	K-BILD	QoL	tool,	while	not	specifically	designed	to	assess	178	
fatigue,	 does	 give	 a	 holistic	 assessment	 of	 patient	 symptoms	 and	 as	 such	 is	 an	 appropriate	179	
comparator	to	the	VASF	and	VASD.	There	are	also	limitations	inherent	to	the	use	of	VAS.	 	These	180	
measures	 are	 subject	 to	 “end	 of	 scale”	 bias,	 wherein	 respondents	 are	 less	 likely	 to	 use	 the	181	
extreme	ends	of	the	scale	to	assess	their	health	status.		Likewise,	it	is	possible	that	while	VAS	are	182	






second	 cohort	of	31	patients,	 is	 similar	 to	 reports	of	dyspnoea	 in	pleural	disease8,	 asthma6	and	189	
COPD7.		VASD	demonstrated	responsiveness	to	change	in	ILD	status	by	correlation	with	changes	in	190	
validated	measures,	 including	 FVC,	 6MWD	 and	 K-BILD15,27.	 In	 contrast,	 change	 in	 VASD	 did	 not	191	







correlate	 with	 FVC%	 and	 DLCO%31,32,	 whereas	 other	 studies	 have	 found	 weak	 but	 statistically	199	
significant	associations1,19,33.	A	clinical	trial	in	patients	with	IPF	found	significant	reductions	in	FVC	200	
were	 not	 associated	 with	 reduced	 dyspnoea	 scores29.	 A	 possible	 explanation	 could	 be	 that	201	







Our	 findings	 show	VASD	 is	 also	associated	with	 validated	patient-reported	measures.	Change	 in	206	
VASD	score	was	associated	with	change	in	Likert	score,	demonstrating	its	ability	to	reflect	patient	207	
experience14.	 Furthermore	 change	 in	 VASD	 correlated	 with	 change	 in	 K-BILD	 scores,	 consistent	208	
with	 previous	 studies	 which	 found	 correlations	 between	 VASD	 and	 other	 quality	 of	 life	209	
assessments	 (r=-0.61)33.	 Finally,	 patient-estimated	MCID	 was	 similar	 to	 anchor-based	 methods,	210	
providing	further	evidence	that	VASD	accurately	reflects	patient	opinion.	211	
	212	
Distributional	methods	 underestimated	 the	MCID	 for	 VASD,	 consistent	with	 a	 study	which	 also	213	
compared	 distributional	 and	 anchor-based	 methods8.	 Distributional	 approaches	 have	 been	214	
criticised	as	 they	do	not	use	clinical	anchors	and	provide	a	purely	 statistical	estimation	of	MCID	215	







VASF	 increased	 in	 association	with	 increased	 Likert	 scale	 response.	 Additionally,	 the	MCID	was	223	
confirmed	 in	 the	 validation	 cohort.	 However,	 there	 were	 wide	 and	 overlapping	 95%	 CI	 for	 all	224	
groups,	 particularly	 those	 reporting	 changes,	 and	 a	 lack	 of	 correlation	 of	 VASF	 with	 other	225	
measures.	 These	 results	 are	 consistent	 with	 a	 study	 which	 found	 VASF	 was	 less	 sensitive	 than	226	
other	scales	for	assessing	fatigue,	whereas	VASD	was	superior35.	227	
	228	
There	 is	 a	 paucity	 of	 studies	which	 have	 looked	 specifically	 at	 the	 prevalence	 of	 fatigue	 in	 ILD,	229	
although	 it	 is	 widely	 understood	 to	 be	 common	 based	 on	 quality	 of	 life	 studies5.	 Predictors	 of	230	
fatigue	 have	 been	 modelled	 for	 IPF	 but	 could	 not	 be	 identified	 for	 sarcoidosis,	 indicating	 the	231	
diverse	 manifestation	 of	 the	 symptom	 amongst	 different	 ILDs36.	 Although	 VASF	 has	 not	 been	232	
investigated	in	ILD,	it	has	been	assessed	in	a	range	of	diseases	including	rheumatoid	arthiritis37	and	233	








The	 correlation	 observed	 between	 VASF	 and	 6MWD	 could	 be	 due	 to	 the	 inclusion	 of	 physical	239	
muscle	 weakness	 secondary	 to	 de-conditioning	 within	 the	 subjective	 perception	 of	 fatigue5.	240	




In	 this	 study	 VASC	 was	 unable	 to	 detect	 change	 in	 cough	 symptoms.	 Previous	 studies	 have	245	
demonstrated	a	 lack	of	 correlation	between	cough	 rates	and	 lung	 function	 tests41	 and	between	246	
subjective	and	objective	measures	of	cough42,43.	Cough	is	a	complex	symptom	of	ILD,	and	there	are	247	
likely	 to	 be	 alternative	 causes	 such	 as	 rhinitis	 and	 gastro-oesophageal	 reflux	 in	 the	 patients	248	











This	 study	 has	 shown	 the	 VAS	 is	 a	 valid	 and	 clinically	 relevant	 tool	 for	 assessing	 change	 in	260	
dyspnoea	 and	 fatigue	 in	 patients	 with	 ILD.	 These	 scales	 correlate	 with	 recognised	 markers	 of	261	
disease,	including	K-BILD	and	pulmonary	physiology	tests.		The	MCID	for	change	in	VAS	is	22.0mm	262	
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No	change	 25	(39)	 4.0	 2-6	
Slight	change	but	not	worthwhile	 16	(25)	 9.0	 6-10	
Small	but	just	worthwhile	change*	 17	(27)	 22.0	 12-35	
Large	or	moderate	change	 6	(9)	 30.0	 12-64	
VAS	
Fatigue	
No	change	 17	(27)	 4.0	 2-9	
Slight	change	but	not	worthwhile	 19	(30)	 11.0	 5-17	
Small	but	just	worthwhile	change*	 18	(28)	 14.5	 8-20	
Large	or	moderate	change	 10	(16)	 20.5	 6-49	
VAS	
Cough	
No	change	 18	(28)	 7.0	 3-18	
Slight	change	but	not	worthwhile	 19	(30)	 10.0	 7-17	
Small	but	just	worthwhile	change*	 18	(28)	 18.0	 15-32	






Table	 3	 	 	 Anchor,	 Distributional	 and	 Patient-opinion	 estimates	 of	 the	 minimal	 clinically	
important	difference	(MCID)*	
	 ES	 ERES	 Anchor-based	 Patient-	opinion	
VAS	Dyspnoea	 7.7	 8.4	 22.0	 20.5	
VAS	Fatigue	 9.0	 8.4	 14.5	 28.0	
N=64	





Table	 4	 	 	 Spearman’s	 correlation	 coefficients	 between	 change	 in	 VAS	 and	 change	 in	 other	
measures	
	 VAS	Dyspnoea	 VAS	Fatigue	 VAS	Cough	
FVC%	 -0.319	(p=0.010)	 -0.275	(p=0.028)	 		0.06	(p=0.635)	
DLCO%	 -0.201	(p=0.124)	 -0.186	(p=0.156)	 -0.012	(p=0.928)	
6MWD	 -0.365	(p=0.007)	 -0.349	(p=0.010)	 	0.045	(p=0.751)	
KBILD	Overall	 -0.506	(p=0.000)	 -0.500	(p=0.000)	 -0.363	(p=0.003)	
KBILD	Specific	 -0.557	(p=0.000)	 -0.423	(p=0.000)	 -0.217	(p=0.085)	
N=64	








	 IPF	 Non-IPF		 p-value	
Mean	baseline	VAS	Dyspnoea,	mm	(SD)	 36	(19)	 34	(25)	 0.459	
Mean	baseline	VAS	Cough,	mm	(SD)	 38	(20)	 44	(29)	 0.490	
Mean	baseline	VAS	Fatigue,	mm	(SD)	 43	(21)	 42	(29)	 0.674	
Change	in	VAS	Dyspnoea,	mm	(SD)	 3	(17)	 2	(21)	 0.603	
Change	in	VAS	Cough,	mm	(SD)	 2	(20)	 -5	(29)	 0.298	

















Change	 in	 VAS	 dyspnoea,	 significant	 between-group	 difference	 (p=0.000).	 B)	 Change	 in	 VAS	413	
Fatigue,	 significant	 between-group	 difference	 (p=0.006)	 C)	 Change	 in	 VAS	 Cough,	 no	 significant	414	
difference	between	groups	(p=0.061).	Definition	of	abbreviations:	VAS,	visual	analogue	scale.	415	
	416	
Figure	4	 	 	Relationship	between	change	 in	VAS	Dyspnoea	and	dyspnoea-specific	 components	of	417	
the	K-BILD	questionnaire.		418	
Circles	represent	individual	data	points	(change	VASD	and	change	in	dyspnoea	components	of	K-419	
BILD).	Solid	like	represents	the	line	of	best	fit.	420	
*Spearman	Rank	correlation	coefficient	421	
Definition	of	abbreviations:	VAS,	visual	analogue	scale;	K-BILD,	King’s	Brief	Interstitial	Lung	Disease	422	
Questionnaire.	423	
 424	
 425	
